{
    "medicine_id": "f6f2b3280037217c47a7fc4d885ab4e6e57c95b0",
    "platform_id": "DB11274",
    "metadata": {
        "name": "Ergoloid Mesylates 20 MG Tablet",
        "composition": "20 MG Dihydro alpha ergocryptine",
        "clinical_particulars": {
            "therapeutic_indications": "Alpha dihydroergocryptine has been studied for the early treatment of Parkinson disease A32980 as well as for its use in migraine prophylaxis A32983 treatment of low blood pressure and peripheral vascular disorder To know more about the ergoloid mesylate mixture and its uses please visit DB01049",
            "contraindications": {
                "disease": "Alpha dihydroergocryptine does not have effect in fertility and it does not present mutagenic potential A33005 To know more about the ergoloid mesylate mixture please visit DB01049",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "The effect of alpha dihydroergocryptine in dopamine receptors was tested in PD patients and seem to generate a significant clinical improvement in the tested patients as well as to reduce motor complications and side effects A32980 In long term clinical trials with Parkinson disease patients the administration of alpha dihydroergocryptine and levodopa the symptoms were reposted to improve or completely vanish in 80 of the tested individuals A32995 All the registered effects of alpha dihydroergocryptine suggest a potential neuroprotective effect of this drug and some reports have indicated that this activity may be related to the activation of NF kB A32997 The effect of alpha dihydroergocryptine in the dopamine D2 receptor also reduces prolactin plasma levels and induce hypotension A32996 To know more about the ergoloid mesylate mixture please visit DB01049",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB11642",
                        "description": "The serum concentration of Dihydro alpha ergocryptine can be decreased when it is combined with Pitolisant"
                    },
                    {
                        "drugbank-id": "DB09046",
                        "description": "The metabolism of Dihydro alpha ergocryptine can be increased when combined with Metreleptin"
                    },
                    {
                        "drugbank-id": "DB06119",
                        "description": "The serum concentration of Dihydro alpha ergocryptine can be decreased when it is combined with Cenobamate"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The serum concentration of Dihydro alpha ergocryptine can be increased when it is combined with Ritonavir"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The serum concentration of Haloperidol can be increased when it is combined with Dihydro alpha ergocryptine"
                    },
                    {
                        "drugbank-id": "DB11652",
                        "description": "The metabolism of Tucatinib can be decreased when combined with Dihydro alpha ergocryptine"
                    },
                    {
                        "drugbank-id": "DB11932",
                        "description": "The serum concentration of Dihydro alpha ergocryptine can be increased when it is combined with Abametapir"
                    },
                    {
                        "drugbank-id": "DB15762",
                        "description": "The serum concentration of Dihydro alpha ergocryptine can be decreased when it is combined with Satralizumab"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}